LLY
Price
$737.67
Change
+$15.10 (+2.09%)
Updated
May 30 closing price
Capitalization
739.66B
67 days until earnings call
PFE
Price
$23.49
Change
+$0.04 (+0.17%)
Updated
May 30 closing price
Capitalization
157.14B
65 days until earnings call
Interact to see
Advertisement

LLY vs PFE

Header iconLLY vs PFE Comparison
Open Charts LLY vs PFEBanner chart's image
Eli Lilly & Co
Price$737.67
Change+$15.10 (+2.09%)
Volume$6.11M
Capitalization739.66B
Pfizer
Price$23.49
Change+$0.04 (+0.17%)
Volume$56.62M
Capitalization157.14B
LLY vs PFE Comparison Chart
Loading...
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LLY vs. PFE commentary
Jun 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Buy and PFE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 02, 2025
Stock price -- (LLY: $737.67 vs. PFE: $23.49)
Brand notoriety: LLY and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: LLY: 140% vs. PFE: 114%
Market capitalization -- LLY: $739.66B vs. PFE: $157.14B
LLY [@Pharmaceuticals: Major] is valued at $739.66B. PFE’s [@Pharmaceuticals: Major] market capitalization is $157.14B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LLY’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • LLY’s FA Score: 2 green, 3 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, LLY is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LLY’s TA Score shows that 3 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).

  • LLY’s TA Score: 3 bullish, 5 bearish.
  • PFE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, PFE is a better buy in the short-term than LLY.

Price Growth

LLY (@Pharmaceuticals: Major) experienced а +3.36% price change this week, while PFE (@Pharmaceuticals: Major) price change was +0.73% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.93%. For the same industry, the average monthly price growth was +1.41%, and the average quarterly price growth was +0.61%.

Reported Earning Dates

LLY is expected to report earnings on Aug 07, 2025.

PFE is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.93% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LLY($740B) has a higher market cap than PFE($157B). LLY has higher P/E ratio than PFE: LLY (131.13) vs PFE (74.92). LLY YTD gains are higher at: -4.086 vs. PFE (-8.278). PFE has higher annual earnings (EBITDA): 9.56B vs. LLY (8.57B). PFE has more cash in the bank: 12.7B vs. LLY (2.93B). LLY has less debt than PFE: LLY (25.2B) vs PFE (70.8B). PFE has higher revenues than LLY: PFE (58.5B) vs LLY (34.1B).
LLYPFELLY / PFE
Capitalization740B157B471%
EBITDA8.57B9.56B90%
Gain YTD-4.086-8.27849%
P/E Ratio131.1374.92175%
Revenue34.1B58.5B58%
Total Cash2.93B12.7B23%
Total Debt25.2B70.8B36%
FUNDAMENTALS RATINGS
LLY vs PFE: Fundamental Ratings
LLY
PFE
OUTLOOK RATING
1..100
6222
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
13100
SMR RATING
1..100
1574
PRICE GROWTH RATING
1..100
6460
P/E GROWTH RATING
1..100
9496
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for LLY (79). This means that PFE’s stock grew significantly faster than LLY’s over the last 12 months.

LLY's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that LLY’s stock grew significantly faster than PFE’s over the last 12 months.

LLY's SMR Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (74). This means that LLY’s stock grew somewhat faster than PFE’s over the last 12 months.

PFE's Price Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as LLY (64). This means that PFE’s stock grew similarly to LLY’s over the last 12 months.

LLY's P/E Growth Rating (94) in the Pharmaceuticals Major industry is in the same range as PFE (96). This means that LLY’s stock grew similarly to PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LLYPFE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
65%
Bearish Trend 3 days ago
57%
Momentum
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
50%
MACD
ODDS (%)
Bearish Trend 3 days ago
45%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
57%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
54%
Bullish Trend 3 days ago
49%
Advances
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
56%
Declines
ODDS (%)
Bearish Trend 10 days ago
53%
Bearish Trend 19 days ago
61%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
60%
Aroon
ODDS (%)
Bearish Trend 3 days ago
52%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IHS5.550.12
+2.21%
IHS Holding Limited
ACGL95.040.84
+0.89%
Arch Capital Group Ltd
CPA107.78-0.43
-0.40%
Copa Holdings SA
BANL0.88-0.04
-4.18%
CBL International Limited
TLSI5.00-0.48
-8.76%
TriSalus Life Sciences

LLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, LLY has been loosely correlated with AZN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LLY
1D Price
Change %
LLY100%
+2.09%
AZN - LLY
45%
Loosely correlated
+2.77%
NVS - LLY
42%
Loosely correlated
+2.82%
OGN - LLY
39%
Loosely correlated
-3.35%
MRK - LLY
32%
Poorly correlated
+0.58%
PFE - LLY
30%
Poorly correlated
+0.17%
More

PFE and

Correlation & Price change

A.I.dvisor indicates that over the last year, PFE has been loosely correlated with AMGN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PFE
1D Price
Change %
PFE100%
+0.17%
AMGN - PFE
56%
Loosely correlated
+1.64%
GSK - PFE
54%
Loosely correlated
+2.57%
ABBV - PFE
54%
Loosely correlated
+0.26%
NVS - PFE
52%
Loosely correlated
+2.82%
JNJ - PFE
49%
Loosely correlated
+1.06%
More